Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic potential of ketamine for alcohol use disorder
Stephen Worrell, Thomas J. Gould
Neuroscience & Biobehavioral Reviews (2021) Vol. 126, pp. 573-589
Closed Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment
Jenessa N. Johnston, Bashkim Kadriu, Josh Allen, et al.
Neuropharmacology (2023) Vol. 226, pp. 109422-109422
Open Access | Times Cited: 32
Narrative Review: Low-Dose Ketamine for Pain Management
Alessandro Riccardi, Mario Guarino, Sossio Serra, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 9, pp. 3256-3256
Open Access | Times Cited: 25
Classic and non‐classic psychedelics for substance use disorder: A review of their historic, past and current research
Fúlvio Rieli Mendes, Cristiane dos Santos Costa, Victor Distefano Wiltenburg, et al.
Addiction Neuroscience (2022) Vol. 3, pp. 100025-100025
Open Access | Times Cited: 33
Active mechanisms of ketamine-assisted psychotherapy: A systematic review
Isak Joneborg, Yena Lee, Joshua D. Di Vincenzo, et al.
Journal of Affective Disorders (2022) Vol. 315, pp. 105-112
Closed Access | Times Cited: 29
Ketamine as a Treatment for Anorexia Nervosa: A Narrative Review
Johanna Louise Keeler, Janet Treasure, Mário F. Juruena, et al.
Nutrients (2021) Vol. 13, Iss. 11, pp. 4158-4158
Open Access | Times Cited: 38
The therapeutic use and efficacy of ketamine in alcohol use disorder and alcohol withdrawal syndrome: a scoping review
Charlotte Goldfine, Jeremiah J. Tom, Dana D. Im, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 14
Impact of psychedelics on craving in addiction: A systematic review
Sophie‐Athéna Chapron, Guilhem Bonazzi, Laura Di Lodovico, et al.
Journal of Psychopharmacology (2025)
Closed Access
Temperature and Steric Hindrance-Regulated Selective Synthesis of Ketamine Derivatives and 2-Aryl-Cycloketone-1-Carboxamides via Nucleophilic Substitution and Favorskii Rearrangement
Haojiang Zhai, Penghui Li, Hongshuang Wang, et al.
Organic & Biomolecular Chemistry (2025)
Closed Access
Qualitative analysis of a patient's experience of ketamine-assisted psychotherapy for substance use disorder: Empirical synergies with twelve-step programs
Dan Petrovitch, Jacob Spinks, H.J. Yoo, et al.
Psychiatry Research Case Reports (2025), pp. 100259-100259
Open Access
Sex specific effects of ketamine, but not other glutamate receptor modulators, on ethanol self-administration and reinstatement of ethanol seeking in rats
Megan L. Bertholomey, Camryn Forbes, Bryan D. McElroy, et al.
Psychopharmacology (2025)
Closed Access
Psilocybin prevents reinstatement of alcohol seeking by disrupting the reconsolidation of alcohol-related memories
Federica Benvenuti, Daniele Colombo, Laura Soverchia, et al.
Psychopharmacology (2023) Vol. 240, Iss. 7, pp. 1521-1530
Open Access | Times Cited: 10
Genitourinary Tissue Engineering: Reconstruction and Research Models
Christophe Caneparo, David Brownell, Stéphane Chabaud, et al.
Bioengineering (2021) Vol. 8, Iss. 7, pp. 99-99
Open Access | Times Cited: 20
Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates
Dale Terasaki, Ryan Loh, Anastasia Cornell, et al.
Addiction Science & Clinical Practice (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 14
Ketamine and Esketamine in Clinical Trials: FDA‐Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations
K. A. Vekhova, Evgeniya D. Namiot, Jörgen Jönsson, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 117, Iss. 2, pp. 374-386
Open Access | Times Cited: 2
Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review
Rafael Vitor Lima da Cruz, Richardson N. Leão, Thiago C. Moulin
Molecular Medicine (2024) Vol. 30, Iss. 1
Open Access | Times Cited: 2
Looking beyond the opioid receptor: A desperate need for new treatments for opioid use disorder
Yu Kyung Lee, Mark S. Gold, Brian Fuehrlein
Journal of the Neurological Sciences (2021) Vol. 432, pp. 120094-120094
Closed Access | Times Cited: 16
Ketamine: From Prescription Anaesthetic to a New Psychoactive Substance
Maria Rosaria Varı̀, Giovanna Ricci, Marco Cavallo, et al.
Current Pharmaceutical Design (2022) Vol. 28, Iss. 15, pp. 1213-1220
Closed Access | Times Cited: 11
Increased Demand for Ketamine Infusions and Associated Complexities
Evan Peskin, Jeffrey Gudin, Michael E. Schatman
Journal of Pain Research (2023) Vol. Volume 16, pp. 295-299
Open Access | Times Cited: 4
Advancements in addressing drug dependence: A review of promising therapeutic strategies and interventions
C Guida, Juliana Marino Maia, Luiz Fernando Romanholo Ferreira, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2024) Vol. 134, pp. 111070-111070
Closed Access | Times Cited: 1
Ketamine: an Emerging Agent in the Management of Neuropsychiatric Disorders
Nathan B. Menke, Elizabeth R. Hoffman, Kelsey Gaylor, et al.
Asian Journal of Psychiatry (2024) Vol. 106, pp. 104351-104351
Closed Access | Times Cited: 1
Ketamine Augmentation of Exposure Response Prevention Therapy for Obsessive-compulsive Disorder.
Hugo Bottemanne, Alice Arnould
PubMed (2022) Vol. 18, Iss. 10-12, pp. 9-11
Closed Access | Times Cited: 7
Substance Use and Addiction in Athletes: The Case for Neuromodulation and Beyond
John W. Dougherty, David Baron
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 23, pp. 16082-16082
Open Access | Times Cited: 6
No time to lose: the current state of research in rapid-acting psychotherapeutics
Joshua A. Gordon, Nora D. Volkow, George F. Koob
Neuropsychopharmacology (2023) Vol. 49, Iss. 1, pp. 10-14
Closed Access | Times Cited: 3
Sculptor and Destroyer
Mark P. Mattson
The MIT Press eBooks (2023)
Closed Access | Times Cited: 2
Helpful or Harmful? The Therapeutic Potential of Medications with Varying Degrees of Abuse Liability in the Treatment of Substance Use Disorders
Bradford Martins, Will Rutland, João P. De Aquino, et al.
Current Addiction Reports (2022) Vol. 9, Iss. 4, pp. 647-659
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top